Skye Bioscience, Inc. (SKYE)
Nasdaq · Healthcare · Biotechnology
$1.73+2.98%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.7M
- 52-week range
- $1.50 – $16.80
- 52-week change
- −87.35%
- EPS (trailing)
- −$10.16
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Net income
- −$55.9M
- Diluted EPS
- −$1.41
- Free cash flow
- −$43.1M
From the company’s annual report on SEC EDGAR.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Headquarters: San Diego, United States · 2 employees · skyebioscience.com